Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2015

View Archived Issues

Osaka University starts phase I/II trial of CNT-01 in patients with idiopathic TGCV

Tohoku University, Gunma University and Fuso disclose OPN production inhibitors

Glycemic improvements similar with omarigliptin and sitagliptin in patients with type 2 diabetes

Pediatric schistosomiasis candidate L-praziquantel safe in phase I study in healthy volunteers

New mutation in HNF1B identified in patient with maturity-onset diabetes of the young type 5

Rat forelimb allotransplantation model enables assessment of function

FDA grants fast track designation to Alcobra's metadoxine extended release

Transgenic pigs used to model gestational diabetes

Glide Technologies and Cilian to develop novel solid dose recombinant influenza vaccine

Palatin Technologies and Richter terminate license agreement for bremelanotide

Saniona reports data supporting the use of Tesomet in type 2 diabetes, plans proof-of-concept study

Artificially designed peptide inhibits HIV fusion with improved pharmacological properties

AcelRx sells portion of Zalviso royalty stream to PDL BioPharma

Phase III induction trials of tofacitinib in ulcerative colitis meet primary endpoints

Companies receive funding to advance Ebola programs

Harbour Antibodies signs new licenses to transgenic mouse platforms

Roche reports compounds for the treatment of hepatitis B

Gilead reports topline results from four phase III studies of sofosbuvir/velpatasvir for HCV

Aerie initiates phase III trial of Roclatan

Akari Therapeutics formed to develop treatments for diseases involving complement C5

Plexxikon discloses c-Kit inhibitors

Clinical effect of K-877 may be superior to fibrate drugs on the market

Taro launches Keveyis for primary hyperkalemic and hypokalemic periodic paralysis

Pharmaxis reports phase I results for PXS-4728A

LFB's IVIg Iqymune approved in U.K. and Denmark

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...